Percy William Cecil Lomax

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.

ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom.